Effect of Vitamin E+Selenium on Kidney Function in Controlled Hypotension
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether Kidney injury happens in controlled hypotension during brain operations by using Neutrophil Gelatinase Associated Lipocalin ELISA Kit and if so, does VitaminE+Selenium prevent it
| Condition | Intervention | Phase |
|---|---|---|
|
Acute Kidney Injury |
Drug: vitamin E +Selenium |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Prevention |
| Official Title: | Assessment of Preventive Effect of Vitamin E +Selenium on Acute Kidney Injury Through NGAL in Patients Undergoing Controlled Hypotension During Neurosurgery Operations |
- increased amount of urinary or serum NGAL after controlled hypotension [ Time Frame: from 2 hours to 24 hours after controlled hypotension ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 60 |
| Study Start Date: | June 2011 |
| Estimated Primary Completion Date: | August 2012 (Final data collection date for primary outcome measure) |
-
Drug: vitamin E +Selenium
NGAL(Neutrophil Gelatinase Associated Lipocalin) is a 25KD protein which bounds with Gelatinase in Neutrophil granules.It is also expressed in epithelial cells of kidney tubules.NGAL increases in ischemic and toxic injuries of kidney. During controlled hypotension in brain operations injury to the kidneys might occur . This study is designed to assess this possibility and evaluate the effect of VitaminE+Selenium on prevention of this problem
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- All patients who are candidate for brain surgery under controlled hypotension
Exclusion Criteria:
- Positive history of renal disease
- Positive history of diabetes mellitus, CHF, HTN, Breast cancer, fever, leukocytosis
Contacts and Locations| Contact: Mahmoodreza Torkaman, resident | 0098 917 105 0954 | MRZTORKAMAN@yahoo.com |
| Iran, Islamic Republic of | |
| Tehran university of medical sciences, Imam Khomeini Hospital, neurosurgery operation room and ward | Recruiting |
| Tehran, Iran, Islamic Republic of | |
| Contact 0098 21 6119 2828 roaf2009@yahoo.com | |
| Principal Investigator: Mahmoodreza Torkaman, Resident | |
More Information
No publications provided
| Responsible Party: | Zahed Hosein Khan, professor, Tehran University of Medical Sciences |
| ClinicalTrials.gov Identifier: | NCT01554345 History of Changes |
| Other Study ID Numbers: | 89-04-30-11624 |
| Study First Received: | February 19, 2012 |
| Last Updated: | March 13, 2012 |
| Health Authority: | Iran: Ethics Committee United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Hypotension Acute Kidney Injury Vascular Diseases Cardiovascular Diseases Renal Insufficiency Kidney Diseases Urologic Diseases Selenium Vitamin E Alpha-Tocopherol Tocopherols |
Tocotrienols Vitamins Trace Elements Micronutrients Growth Substances Physiological Effects of Drugs Pharmacologic Actions Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents |
ClinicalTrials.gov processed this record on May 22, 2013